The obesity treatment market is explosive.

Look at Eli Lilly (LLY), for example. 

The stock exploded from about $460 to a high of $782 just over excitement with its obesity treatment. It also just blew earnings out of the water, thanks in part to obesity drug sales. In fact, sales of its Zepbound treatment rocketed to $175.8 million in less than a month, according to Seeking Alpha. That was well ahead of the $75 million expected by Wall Street.

Or, look at Viking Therapeutics (VKTX), which we mentioned in mid-December, as it traded at around $19 a share. At the time, we noted, “We can also look at Viking Therapeutics (VKTX), and its potential treatment for obesity – VK2735, which has shown a mean weight loss of up to 18 pounds from baseline. The company also initiated Phase 1 clinical study to evaluate a novel oral formulation of VK2735.  The company believes the potential to provide both a subcutaneously injected and an oral dosage form represent a significant expansion of the opportunity for VK2735.”

Today, VKTX is up to $37.22 and could soon see $50, we believe.

All thanks to takeover speculation, and news the company will have study results before the end of the first quarter, and not “sometime in the first half of the year,” according to Investors’ Business Daily.

There’s also Altimmune (ALT), which we also mentioned in December, as it traded at around $5.60. It’s now up to $8.76, and could also push aggressively higher. “CEO Vipin Garg said the company needs to strike a partnership or a deal with a larger pharmaceutical company to move ahead to phase 3 clinical trials and work toward launching the drug known as pemvidutide,” says CNBC.

If you’re looking for opportunity in the market, keep an eye on obesity drug stocks like these.